Phase II study of nimustine in metastatic soft tissue sarcoma

D. J Th Wagener, R. Somers, A. Santoro, J. Verweij, P. J. Woll, G. Blackledge, H. J. Schütte, M. A. Lentz, M. van Glabbeke

Research output: Contribution to journalArticle

Abstract

The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.

Original languageEnglish
Pages (from-to)1604-1605
Number of pages2
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number12
DOIs
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of nimustine in metastatic soft tissue sarcoma'. Together they form a unique fingerprint.

  • Cite this

    Wagener, D. J. T., Somers, R., Santoro, A., Verweij, J., Woll, P. J., Blackledge, G., Schütte, H. J., Lentz, M. A., & van Glabbeke, M. (1991). Phase II study of nimustine in metastatic soft tissue sarcoma. European Journal of Cancer and Clinical Oncology, 27(12), 1604-1605. https://doi.org/10.1016/0277-5379(91)90424-C